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the base case for savings to be eliminated, and that even without
herd immunity, vaccination would lead to signiﬁcant savings.
With herd immunity of 20%, vaccination remains cost-saving
even if its cost exceeds $100 per immunization and, without herd
immunity, up to a cost of $34. CONCLUSIONS: Based on recent
estimates of pertussis incidence and assuming that the conse-
quences of these previously unreported cases are similar to those
of cases described in the literature, vaccinating adolescents
against pertussis appears an attractive strategy.
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OBJECTIVES: In immunocompromised patients, presumed sys-
temic fungal infections (PSFI) are treated empirically with an
intravenous antifungal to reduce the occurrence of documented
infections and associated mortality. In the Korean health care
setting, conventional amphotericin B (CAB) is currently the
single ﬁrst line treatment choice. However, its toxicity often
results in discontinuation or suboptimal dosing. Liposomal or
lipid formulations of amphotericin B, with improved toxicity
proﬁle, remain restricted for second line use due to their high
acquisition cost. The objective was to compare the cost-
effectiveness of intravenous itraconazole (IVitra) with CAB as
ﬁrst line empirical treatment of presumed SFI in neutropenic
cancer and bone marrow transplant (BMT) patients.
METHODS: A medical decision tree was developed, including
probabilities of toxicity, response, pathogen documentation and
second line treatments. Clinical data were obtained from ran-
domized trials comparing IVitra with CAB (n = 392) and CAB
with LAB (n = 687). Resource use was obtained from a panel of
clinical experts, unit costs from ofﬁcial sources (public payer per-
spective). Cost-effectiveness was expressed as cost per additional
responder (deﬁned as patient without fever or major toxicity).
RESULTS: The total cost of PSFI per neutropenic cancer patient
was lower for IVitra ($7234) than for CAB ($8023). The same
cost ranking was obtained in BMT patients, however with higher
hospitalization costs. The variables accounting for cost differ-
ences were ﬁrst and second line antifungal drug costs and costs
of concomitant drugs. In cost-effectiveness analysis, IVitra was
dominant over CAB combining greater effectiveness (because of
less toxicity) and lower costs. The result was robust to wide vari-
ations in expert reported medical practice. CONCLUSION:
IVitra was shown to be a cost-effective and cost saving alterna-
tive to CAB for empirical treatment of presumed SFI in neu-
tropenic cancer and BMT patients. These conclusions are in line
with those obtained in different European countries, applying the
same methodology.
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OBJECTIVE: To assess the cost effectiveness of an immunisa-
tion programme for rotavirus-associated gastroenteritis among
children aged ﬁve years old and under in the UK. METHOD:
Economic evaluation based on a decision analytical model using
data from a review of published evidence was used. Incremental
cost effectiveness ratios are estimated from both the societal and
health sector perspectives. RESULTS: Using conservative vaccine
efﬁcacy estimates, current immunisation rates and a vaccine cost
of £60 per completed course, rotavirus immunisation would
incur a net health sector cost of £27.8 million per birth cohort
(£42.52 per child). A vaccination programme could, however,
provide net savings to society of £4.8 million; that is, from 
the societal perspective a programme of vaccinating against
rotavirus dominates the alternative of no programme by pre-
venting more cases and costing less. Threshold analysis identi-
ﬁed a breakeven price of £13.26 per course, such that any price
less than this would also result in cost savings for the health
sector. These results are, however, sensitive to a range of vari-
ables and, in particular, society’s cost savings are negated if
parents spend less time away from employment and/or forego
less income. CONCLUSIONS: It appears that some of the health
sector costs and all of the societal costs of gastroenteritis in chil-
dren can be avoided by an immunisation programme using 
one of the two vaccines recently developed. The net cost to the
health sector may, however, be considered worthwhile if there is
a sufﬁcient improvement in the quality-of-life of children and
parents affected by gastroenteritis; this study did not ﬁnd any
evidence of research which has measured the utility gains from
vaccination.
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OBJECTIVES: Meningococcal disease can have severe conse-
quences, and outbreaks require immediate outlay of resources.
Menactra, a new conjugate vaccine for meningococcal disease,
provides protection against serogroups A, C, Y and W-135. This
study examines the cost-effectiveness of routinely vaccinating
adolescents in the US with Menactra. METHODS: The eco-
nomic implications of meningococcal disease vaccination in the
US were assessed using a discrete event simulation. These analy-
ses compare routine vaccination of 12-year-olds with Menactra
to no routine vaccination. Both the direct beneﬁts of vaccination
and the indirect ones resulting from herd immunity are modeled.
The impact of vaccination on outbreaks of disease is also
modeled. Outcomes include cases, deaths, sequelae, life years
lost, quality adjusted life years (QALYs) lost and both direct and
indirect costs (2003 USD). In the base case, the vaccine price was
$70. Vaccine efﬁcacy was assumed to be 90% over 10 years. All
outcomes are discounted at 3% per annum. RESULTS: Without
vaccination, there is an average of 2808 cases per year and 375
deaths. A total of 2.9 community-based and 6.1 school-based
outbreaks per year are predicted. The cost of meningococcal
disease averages $311 million per year. Routine vaccination
reduces the number of cases to under 2000, deaths to 230, com-
munity outbreaks to 0.7 and school-based outbreaks to 1.7.
Disease costs are reduced by over $100 million, but vaccination
increases total costs, resulting in a cost per discounted QALY
gained of $36,868. Sensitivity analyses reveal that outcomes are
strongly inﬂuenced by the duration of protection conferred on
those vaccinated, and the extent of herd immunity resulting from
routine immunization. CONCLUSION: Vaccinating adolescents
in the US with Menactra will reduce burden of disease and can
be cost-effective. Outcomes should be reevaluated as more data
become available.
